Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BLPH Bellerophon Therapeutics
1.030
+0.001+0.10%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-90.75% -109.850% -47.52% -84.251% 46.31% -69.572% 46.85% -56.835%
ROE
-91.62% -114.916% -48.26% -88.029% 49.11% -72.764% 49.82% -59.317%
ROA
-78.67% -86.911% -36.92% -68.062% 40.19% -56.104% 41.01% -46.051%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- 4.68% -159.976%
ROA 5 Year Average
-- -- -- -- -- -- 6.17% -72.616%
Average 5 Years ROIC
-- -- -- -- -- -- 5.84% -139.116%
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- -- -- -- -97.88% 0.050% -62.43% 0.939%
Total Assets to Common Equity
39.79% 169.736% 17.19% 144.381% 5.59% 134.477% -5.36% 124.312%
Debt to Asset Ratio
21.04% 5.331% 9.30% 4.772% 6.36% 4.781% 1.78% 4.417%
Current Ratio
-59.83% 2.3284 -44.98% 3.1176 -25.89% 3.686 9.35% 5.0394
Quick Ratio
-60.98% 2.1852 -45.59% 2.9965 -26.75% 3.5932 7.41% 4.8963
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -- 0.000%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
CEO: Mr. Peter Fernandes
Market: NASDAQ
Listing Date: 02/13/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist